MEDIR Medulloblastome (MEDIR)

September 8, 2010 updated by: University Hospital, Grenoble

Médulloblastome of the Child and After-effects Cognitive: Study Anatomo-functional by IRM of the Working Memory

The medulloblastome is a tumour of the child relatively frequent usually sitting in the cerebellum and treated by surgery, radiotherapy and chemotherapy. After the treatment, these children present cognitive disorders and in particular disorders of the working memory associated with a fall with the school performances. By studying a troop of 32 children, we could show that the disorders of the working memory prevail during the handling of information presented visually and with verbal contents. However, the specific engagement of the cerebellum in the tasks of working memory according to the sensory method of presentation (visual or auditive) and the nature (verbal or not verbal) of information to treat vague remainder. Moreover, the anatomical attacks associated with these disorders remain ignored in these children. The best comprehension of the bases anatomo-functional calculuses which underlie their cognitive deficits is essential to develop new strategies of treatment and rehabilitation.

Objectives:

  • To describe in IRMf of the common and specific networks engaged during the execution of the tasks of working memory according to the sensory type and the nature of information to be memorized.
  • To describe in IRMf the cortical reorganizations necessary to the execution of the mnemic tasks among patients.
  • To describe in anatomical IRM and of the tensor of diffusion lesions cérébelleuses and cerebral, cortical and subcortical associated with these disorders.
  • To study the correlations radio-private clinics between data IRM and the data neurological and neuropsychological of the children explored according to protocol ONCORAP

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The functional study should make it possible to show the specifically committed networks according to the cognitive tasks. Among patients, the relative difficulty to carry out the tasks of working memory should be accompanied by a recruitment of the dorso-side cortex préfrontal, lower and parietal frontal cortex but also of the median frontal areas such as the additional driving surface, the former cingulum. Moreover, one deterioration of the engagement of the cérébello-cerebral network (left lower parietal cortex and cérébelleux cortex lower right) facilitating the execution of these tasks should be observed.

Study Type

Observational

Enrollment (Anticipated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Bordeaux, France, 33076
        • Recruiting
        • University Hospital
        • Sub-Investigator:
          • Michèle M ALLARD
        • Sub-Investigator:
          • Céline C BOUCHN ICHER
        • Sub-Investigator:
          • Muriel M BRUN
        • Sub-Investigator:
          • Anne A NOTZ CARRERE
        • Sub-Investigator:
          • Yves y PEREL
      • Grenoble, France, 38043
        • Recruiting
        • UniversityHospitalGrenoble
        • Contact:
        • Sub-Investigator:
          • Alexandre A KRAINIK
        • Sub-Investigator:
          • Dominique D PLANTAZ
        • Sub-Investigator:
          • Corinne C ARAMARI ALLA
        • Sub-Investigator:
          • FANNY F DUBOIS
        • Sub-Investigator:
          • CHANTAL C DURAND
      • Lyon, France, 69008
        • Recruiting
        • Institut D'Hematologie Et D'Oncologie Pediatrique
        • Sub-Investigator:
          • Cécile c CONTER
        • Sub-Investigator:
          • DIDIER D FRAPPAZ
      • Paris, France, 75015
        • Recruiting
        • Hôpital Frédéric Joliot Orsay - Hôpital Necker
        • Sub-Investigator:
          • Lucie L HERTZ PANNIER
        • Sub-Investigator:
          • Rodrigo R SEBASTIAN
      • Paris, France, 75231
        • Recruiting
        • Institut Curie
        • Sub-Investigator:
          • Isabelle i AERTS
        • Sub-Investigator:
          • François F DOZ
        • Sub-Investigator:
          • Sylvie S FASOLA
        • Sub-Investigator:
          • Jean J MICHON
        • Sub-Investigator:
          • Daniel D ORBACH
        • Sub-Investigator:
          • Hélène H PACQUEMENT
        • Sub-Investigator:
          • GILLES G PALENZUELA
        • Sub-Investigator:
          • GUDRUN G SCHLEIERMACHER
      • Saint Etienne, France, 42055
        • Recruiting
        • University Hospital
        • Sub-Investigator:
          • CLAIRE C BERGER
        • Sub-Investigator:
          • FABRICE F BARRAL
        • Sub-Investigator:
          • CATHERINE C MASSOUBRE
        • Sub-Investigator:
          • JEAN LOUIS JL STEPHAN
      • Villejuif, France, 94805
        • Recruiting
        • Institut Gutave Roussy
        • Sub-Investigator:
          • jacques j Grill
      • Villeurbanne, France, 69100
        • Recruiting
        • SMAEC
        • Sub-Investigator:
          • Sybille S GONZALEZ

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 12 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

child Treaties for a médulloblastome after the 6 years age

Description

Inclusion Criteria:

  • Old from 8 to 12 years
  • Total IQ > 70 for the participation in the study and/or age développemental 7 years minimum
  • Treaties for a médulloblastome after the 6 years age in remission supplements with 6 months a minimum time compared to the end of all the treatments
  • Followed within the framework of the protocol of evaluation of the mnemic and attentionnelles after-effects
  • Sensory after-effects compatible with the realization of the tasks and good performances at the time of the preceding drive the IRM
  • Absence of counter-indication to the IRM
  • Absence of catch of méthylphénidate (Ritaline®) for the treatment of disorders attentionnels 48h before the IRM
  • Enlightened assent signed by at least one of the two parents or holders of the parental authority and by the child (minor)

Exclusion Criteria:

  • Agitation or movements of the head at the time the IRM
  • Artifacts of magnetic susceptibility in projection of the areas of interest (intracranial haemorrhage, cortical and/or metal remains post-operative) • Bad execution of the cognitive tasks
  • Tumoral relapse in the course of protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
healthy volonteer children
paired for the sex and the age
IRMf BOLD of the working memory
older children followed for a médulloblastome cérébelleux
children followed for a médulloblastome treaty by surgery, radiotherapy and chemotherapy
IRMf BOLD of the working memory

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anne A PAGNIER, Doctor, University Hospital, Grenoble

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Primary Completion (Anticipated)

July 1, 2012

Study Completion (Anticipated)

July 1, 2012

Study Registration Dates

First Submitted

September 7, 2010

First Submitted That Met QC Criteria

September 8, 2010

First Posted (Estimate)

September 9, 2010

Study Record Updates

Last Update Posted (Estimate)

September 9, 2010

Last Update Submitted That Met QC Criteria

September 8, 2010

Last Verified

September 1, 2010

More Information

Terms related to this study

Other Study ID Numbers

  • 07PHN01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Child Cancer Brain

Clinical Trials on IRMf Bold

3
Subscribe